Seebri Breezhaler
glycopyrronium bromide
Table of contents
Overview
Seebri Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Seebri Breezhaler is used for maintenance (regular) treatment.
Seebri Breezhaler contains the active substance glycopyrronium bromide.
-
List item
Seebri Breezhaler : EPAR - Medicine overview (PDF/68.54 KB)
First published: 17/10/2012
Last updated: 05/07/2018
EMA/434336/2012 -
-
List item
Seebri Breezhaler : EPAR - Risk-management-plan summary (PDF/138.35 KB)
First published: 05/07/2018
Last updated: 05/07/2018
Authorisation details
Product details | |
---|---|
Name |
Seebri Breezhaler
|
Agency product number |
EMEA/H/C/002430
|
Active substance |
Glycopyrronium bromide
|
International non-proprietary name (INN) or common name |
glycopyrronium bromide
|
Therapeutic area (MeSH) |
Pulmonary Disease, Chronic Obstructive
|
Anatomical therapeutic chemical (ATC) code |
R03BB06
|
Publication details | |
---|---|
Marketing-authorisation holder |
Novartis Europharm Limited
|
Revision |
12
|
Date of issue of marketing authorisation valid throughout the European Union |
28/09/2012
|
Contact address |
Vista Building |
Product information
28/10/2021 Seebri Breezhaler - EMEA/H/C/002430 - WS/2176
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Drugs for obstructive airway diseases
Therapeutic indication
Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).